RxSight (NASDAQ:RXST – Get Free Report) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.
Institutional and Insider Ownership
78.8% of RxSight shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares RxSight and Fresenius Medical Care AG & Co. KGaA”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RxSight | $134.48 million | 1.87 | -$38.94 million | ($1.13) | -5.39 |
| Fresenius Medical Care AG & Co. KGaA | $22.20 billion | 0.55 | $1.11 billion | $1.90 | 11.42 |
Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
RxSight has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for RxSight and Fresenius Medical Care AG & Co. KGaA, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RxSight | 3 | 10 | 2 | 0 | 1.93 |
| Fresenius Medical Care AG & Co. KGaA | 4 | 5 | 0 | 0 | 1.56 |
RxSight presently has a consensus price target of $9.44, suggesting a potential upside of 55.08%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $28.00, suggesting a potential upside of 29.06%. Given RxSight’s stronger consensus rating and higher probable upside, equities analysts clearly believe RxSight is more favorable than Fresenius Medical Care AG & Co. KGaA.
Profitability
This table compares RxSight and Fresenius Medical Care AG & Co. KGaA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RxSight | -36.58% | -17.01% | -15.12% |
| Fresenius Medical Care AG & Co. KGaA | 4.88% | 8.90% | 4.05% |
About RxSight
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
